Home › Funds › Palogic Value Management, L.P. › HCAT
Palogic Value Management, L.P. position in HCAT
HEALTH CATALYST INC · Information Technology
Palogic Value Management, L.P. reported holding 4,922,442 shares of HCAT (HEALTH CATALYST INC) in its Q2 2026 13F filing — a position valued at US$9.8M, representing 3.31% of its reported portfolio and ranking #5 among its reported holdings. Palogic Value Management, L.P. has disclosed HCAT holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Palogic Value Management, L.P.'s HCAT position evolved
Palogic Value Management, L.P. first disclosed a stake in HCAT in Q4 2024 at 320,000 shares (US$2.3M). The position peaked in Q2 2026 at 4,922,442 shares, worth US$9.8M. Across 7 filings, Palogic Value Management, L.P. increased the stake 6 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 4,922,442 shares valued at US$9.8M — an increase of 2,025,842 shares quarter over quarter.. Notable position changes include a 103% increase in Q1 2025 (shares fell 17% over the following quarter), a 128% increase in Q1 2026 (shares rose 57% over the following quarter), a 70% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 320.00K | $2.26M | New |
| Q1 2025 | 650.00K | $2.94M | Add |
| Q2 2025 | 730.10K | $2.75M | Add |
| Q3 2025 | 1.09M | $3.11M | Add |
| Q4 2025 | 1.27M | $3.04M | Add |
| Q1 2026 | 2.90M | $3.68M | Add |
| Q2 2026 | 4.92M | $9.80M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About HCAT and 13F data
HCAT (HEALTH CATALYST INC) is a Information Technology company. 7 other funds we track also report a position in HCAT — the largest reported positions include First Light Asset Management, LLC (US$25.5M), CDC Financial, Inc. (US$14.1M), Nepsis Inc. (US$5.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding HCAT
- First Light Asset Management, LLC 12.81M sh · $25.49M · Q2 2026
- CDC Financial, Inc. 7.09M sh · $14.11M · Q2 2026
- Nepsis Inc. 2.99M sh · $5.17M · Q3 2026
More on Palogic Value Management, L.P.
FAQ
How long has Palogic Value Management, L.P. held HCAT?
Palogic Value Management, L.P. has disclosed HCAT holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Palogic Value Management, L.P.'s current position in HCAT?
As of Q2 2026, Palogic Value Management, L.P. holds 4.92M shares of HCAT (HEALTH CATALYST INC), valued at $9.80M, representing 3.31% of its reported portfolio and ranking #5.
Has Palogic Value Management, L.P. been buying or selling HCAT?
In the latest 13F filing (Q2 2026), Palogic Value Management, L.P. increased its position in HCAT. The position peaked in Q2 2026 at 4.92M shares.
Which other funds hold HCAT?
Other major institutional holders of HCAT include First Light Asset Management, LLC, CDC Financial, Inc., Nepsis Inc., among 7 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.